CELLTRION

44th Annual J.P. Morgan Healthcare Conference



Jinseok Seo, CEO
Hyukjae Lee, Senior EVP

January 13th, 2026

Disclaimer

This document contains "forward-looking statements" - that is statements related to future not past events. In this context "forward-looking statements" often address our expected future business and financial performance and often contain words such as "expects" "anticipates" "intends" "plans" "believes" "seeks" or "will". "Forward-looking statements" by their nature address matters that are to different degrees uncertain. Therefore, the recipients of this document shall be aware that the forward looking statements set forth herein may not correspond to the actual business performance of the company due to changes in the business/industry environment and the long term business plan of the company.

The financial information contained in this document is consolidated earnings results based on K IFRS. This document is provided for the convenience of investors only before the external audit is completed. The audit outcomes may cause some changes in this document.

The purpose of this document is not to recommend investment in the company. The company hereby expressly disclaims any and all liability resulting from investors' reliance on the information contained herein.

Celltrion: From a Biosimilar Pioneer to an Innovator

Korea's first large-scale antibody facility

World's first mAb biosimilar

New drug development powered by antibody capabilities

Biosimilars: Portfolio-Led Sustainable Growth



Target markets to expand > 4x by 2038

From Biosimilar Excellence

to Next-Gen Innovative Therapeutics

Innovative Drug Pipeline Strategy

ADC[1)]

- Biobetter ADC
- Bispecific ADC
- Dual-payload ADC

MsAb[2)]

- Tumor-selective MsAb
- Conditionally-active MsAb
- Other Immuno-oncology MsAb

1) ADC, Antibody-Drug Conjugate; 2) MsAb, Multi-specific Antibody

Innovative Pipeline: Timeline & Milestones

Key clinical readouts expected **in 2026-2027 with global clinical trials advancing** across regions



ADC Competitive Landscape in Korea

Leading the ADC field with advanced development & clinical execution

Numerous
ADC developers in Korea

Only 8
entered clinical stages

Only **Celltrion**
in-house Topo1i ADC
in the clinic

Celltrion's Recent ADC Achievements : Preclinical Comparison

PBX-7016: superior safety profile vs. benchmark, enabling **higher dose & enhanced efficacy** via a wider TI[1)]



	Emrelis	Padcev	Tivdak	CT-P70		CT-P71		CT-P73	
	GLP[2)]	GLP	GLP	GLP*	DRF[3)]	GLP*	DRF	GLP*	DRF
HNSTD[4)]	3	3	3	25		30		30	
Lethal Dose	Not reached	6	5	Not reached		Not reached		Not reached	

Therapeutic Window



1) TI, Therapeutic Index; 2) GLP, Good Laboratory Practice; 3) DRF, Dose Range Finding; 4) HNSTD, Highest Non-Severely Toxic Dose; 5) RP2D, Recommended Phase 2 Dose; 6) MED, Minimum Effective Dose
*Details of GLP Toxicity study of Celltrion's pipelines: n=3F/3M + 2F/2M recovery; dosing: Q3W x 3 (30min infusion); necropsy: 7 days after last dosing; recovery: 6 to 8 weeks after last dosing.

IND Submission Timeline for Innovative Drug Pipeline



1) NSCLC, Non-Small Cell Lung Cancer; 2) CRC, Colorectal Cancer; 3) UC, Urothelial Carcinoma; 4) H&N, Head and Neck Cancer

Accelerating Innovative Drug Development via Open Innovation

Partnering with domestic and global biotechs: in-licensing, platforms, co-development

	2022	2023	2024	2025
Antibody	PINOTBIO CT-P70, CT-P71, CT-P73	CYRUS THERAPEUTICS NBD 04		mustbio NBD 18
	abpro® CT-P72			TRIOAR R&D Collaboration
				Kaigene CT-P77, NBD 19
Microbiome	KOBIOLABS R&D Collaboration	HEM Pharma R&D Collaboration	BioThe R&D Collaboration	BioThe R&D Collaboration
		LISCure R&D Collaboration		
CGT[1]		GENEMEDICINE R&D Collaboration		
		CUROCELL Strategic Investment		
AI			basgenbio R&D Collaboration	Portrai R&D Collaboration
				Galux R&D Collaboration
				AinB R&D Collaboration
Small Molecule				onconic therapeutics R&D Collaboration
				epibiotech R&D Collaboration
Peptide				TwinpigBiolab R&D Collaboration



1) CGT, Cell & Gene Therapy

Scaling Our U.S. Presence

with a Next-Gen Manufacturing and R&D Hub

Our New U.S. Manufacturing Facility

Strategic acquisition to **drive future growth**

Acquired Asset

DS manufacturing facility of Imclone Systems

A subsidiary of Eli Lilly

CAPA

66,000L

A state-of-the-art, fully modernized manufacturing facility

Acquisition Cost

$ 330M

One-third the cost of building a new facility

~5 years faster than new construction

Strategic Benefits of U.S. Facility Acquisition

Strengthening global supply chain, production, and operations

Building End-to-End U.S. Supply Chain

Market Access Expansion

- Eliminating tariff and trade risks
- Securing DS and DP capacity in U.S.
- 41 launches through 2038

Improved Market Responsiveness Via

Geographic Diversification & Scale-up

- Diversifying DS production sites beyond Korea to enhance supply stability
- Scalable capacity to meet strong U.S. demand
- Additional revenue via CMO contracts

Immediate Operations

Rapid Earnings Contribution

- CMO for Eli Lilly starting 2026

Full Employment Succession

Skilled Workforce Retention

Scaling Our U.S. Manufacturing Facility

Strategic manufacturing & R&D expansion for **long-term growth**

DS Capacity Expansion

Planned DP Capability Build-out

In-house manufacturing for supply stability

Global R&D Center Establishment

Attracting global talent
from NJ-area universities

Enhancing open innovation
in the NJ biotech cluster

Manufacturing hub for
Celltrion products and CMO operations

U.S. R&D platform for
advancing drug development

Thank you



Q&A